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Abstract
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and a
major cause of morbidity among children with pediatric rheumatic diseases. The management of JDM is very
heterogeneous. The JDM working group of the Society for Pediatric Rheumatology (GKJR) aims to define
consensus- and practice-based strategies in order to harmonize diagnosis, treatment and monitoring of JDM.
Methods: The JDM working group was established in 2015 consisting of 23 pediatric rheumatologists, pediatric
neurologists and dermatologists with expertise in the management of JDM. Current practice patterns of
management in JDM had previously been identified via an online survey among pediatric rheumatologists and
neurologists. Using a consensus process consisting of online surveys and a face-to-face consensus conference
statements were defined regarding the diagnosis, treatment and monitoring of JDM. During the conference
consensus was achieved via nominal group technique. Voting took place using an electronic audience response
system, and at least 80% consensus was required for individual statements.
Results: Overall 10 individual statements were developed, finally reaching a consensus of 92 to 100% regarding (1)
establishing a diagnosis, (2) case definitions for the application of the strategies (moderate and severe JDM), (3)
initial diagnostic testing, (4) monitoring and documentation, (5) treatment targets within the context of a treat-to-
target strategy, (6) supportive therapies, (7) explicit definition of a treat-to-target strategy, (8) various glucocorticoid
regimens, including intermittent intravenous methylprednisolone pulse and high-dose oral glucocorticoid therapies
with tapering, (9) initial glucocorticoid-sparing therapy and (10) management of refractory disease.
Conclusion: Using a consensus process among JDM experts, statements regarding the management of JDM were
defined. These statements and the strategies aid in the management of patients with moderate and severe JDM.
Keywords: Dermatomyositis, Child, Consensus, Diagnosis, Antirheumatic agents, Comparative effectiveness research
* Correspondence: claas.hinze@ukmuenster.de
1Department of Pediatric Rheumatology and Immunology, University
Hospital Münster, Albert-Schweitzer-Campus 1, Building D3, 48149 Münster,
Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hinze et al. Pediatric Rheumatology  (2018) 16:40 
https://doi.org/10.1186/s12969-018-0257-6
Background
Juvenile dermatomyositis (JDM) is the most common in-
flammatory myopathy of childhood and a major cause of
morbidity and mortality among patients with pediatric
rheumatic diseases [1]. The management of JDM is highly
variable internationally [2, 3]. Few controlled trials have
been performed on the treatment of JDM, e.g. on metho-
trexate (MTX), cyclosporin A (CSA) and rituximab (RTX)
[4, 5]. The type of glucocorticoid regimen used is especially
variable, with many centers using high-dose oral gluco-
corticoid therapy while others use intermittent intravenous
methylprednisolone pulse therapy [6–10]. Multiple smaller
open label or retrospective studies have been performed,
e.g. on cyclophosphamide (CYC), tumor necrosis factor in-
hibitors (TNFi), high-dose intravenous immune globulins
(IVIG), or mycophenolate mofetil (MMF) [9, 11–13].
Frequently, treatment is based on expert opinion [1, 6, 14].
Notably, only few formally approved treatment options exist
for the treatment of dermatomyositis (DM), in Germany,
including various glucocorticoids (methylprednisolone,
prednisolone, prednisone, dexamethasone, triamcinolone),
azathioprin [AZA], and, under certain conditions, IVIG)
[15]. However, none of these medications have been specif-
ically approved for the use in JDM. Recently, consensus
treatment plans have been established in North America by
the Childhood Arthritis & Rheumatology Research Alliance
(CARRA) and consensus-based treatment recommenda-
tions were developed by the Single Hub and Access point
for pediatric Rheumatology in Europe (SHARE) initiative
[16, 17]. The role of biologic agents in the management of
JDM is less well defined, even though they are frequently
used as outlined by a recent survey among CARRA mem-
bers [18]. However, there is evidence that treatment ap-
proaches for JDM in Germany vary in several aspects from
those used in other countries, including the choice of
glucocorticoid therapy regimens [19]. Lately, the concept
of treat-to-target and tight control has been a cornerstone
of current treatment recommendations for rheumatoid
arthritis, systemic lupus erythematosus and gout, and has
been discussed for pediatric rheumatic diseases as well
[20–24].
The PRO-KIND (PROjekte zur Klassifikation, Überwa-
chung und Therapie in der KINDerrheumatologie; projects
for the classification, monitoring and therapy in pediatric
rheumatology) initiative is a sub-committee of the Society
for Pediatric Rheumatology (GKJR) in Germany and Austria
and aims to define consensus-based plans to harmonize
diagnostic and treatment approaches. This initiative was
started since it was perceived that children with juvenile
rheumatic diseases in Germany and Austria often are either
treated too late or not treated with the most up-to-date
therapeutic regimens. To meet this challenge, the goal of
the PRO-KIND initiative is to foster the use of harmonized
diagnostic and treatment plans with defined targets [25, 26].
Previously, the JDM working group had identified current
practice patterns in Germany and Austria among pediatric
rheumatologists and neurologists [19].
As a next step, the goal of the PRO-KIND working
group on JDM was to harmonize previously identified
patterns into plans and statements.
Methods
PRO-KIND JDM working group and expert panel
The JDM working group was formed in April 2015, ini-
tially comprised of 12 pediatric rheumatologists with
clinical expertise in the management of patients with
JDM. Identification of project goals took place via a formal
online survey using the web-based program SurveyMon-
key (SurveyMonkey Inc.; San Mateo, California, USA;
www.surveymonkey.com). Nine pediatric rheumatologists
participated in an initial face-to-face meeting in January
2016. There was consensus that the expert panel should
also include expert pediatric neurologists. Therefore, 2
pediatric neurologists with special expertise in managing
JDM (W. M-F. and U.S.) were also invited to join the
group, forming an extended interdisciplinary expert panel.
Consensus conference
An extended expert panel with 13 voting members (11
pediatric rheumatologists, 2 pediatric neurologists) and a
non-voting dermatologist experienced in the care of chil-
dren with JDM participated in a final face-to-face consen-
sus meeting on January 13, 2017. The extended expert
panel overlapped with but was not identical with the
members of the initial working group. Prior to the consen-
sus conference, the voting members had received access
to various essential data via sciebo, a cloud service hosted
by the state of Northrhine-Westphalia. The data provided
included detailed results of previous online surveys, previ-
ous meeting protocols, essential literature obtained via an
extensive literature search (but not formally graded), in-
cluding the 112 papers that were scored by SHARE [16].
The process was guided by a psychologist trained as a pro-
fessional moderator. We used nominal group technique
for consensus building. For each individual statement, the
following procedures were performed: the statement and
its background were presented by one of the co-authors
(C.H.) who had formulated the statement in question.
Subsequently, every participant of the consensus confer-
ence had 1 min of time available to raise issues with the
statement being discussed. These issues were recorded on
a flip-chart. Then there was a 15-min open discussion of
these items to further improve the statement. Changes to
the statement were made ad hoc by another co-author
(P.O.) using the PowerPoint presentation program, visible
to all participants. Finally, anonymous voting took place
during which each participant could either accept or reject
the respective statement via an electronic audience
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response system. Consensus was considered to be present
if at least 80% of experts supported a statement.
Results
Expert panel
The expert status of the panel members is demonstrated
by the fact that centers represented in the panel contributed
more than half of all patients (for example, in 2016: 72 out
of 127 [57%]) with JDM documented within the National
Pediatric Rheumatic Disease Database (“Kerndokumentation
rheumakranker Kinder und Jugendlicher”).
Diagnosis and case definition
Regarding the diagnosis of JDM, there was consensus
that the conventional Bohan and Peter criteria should be
modified. In particular, there was consensus that typical
magnetic resonance imaging (MRI) findings represented
an important finding for establishing a diagnosis of
JDM. Furthermore, electromyography was removed from
the list of findings. The finding of symmetric proximal
muscle weakness was modified to also include myalgia
as a possible criterion (Table 1). Concerning the state-
ments developed and the resulting treatment strategies,
the group devised a case definition for moderate and severe
JDM, similar to an existing CARRA definition (Table 1)
[17]. According to the consensus, all patients with active
moderate or severe JDM may be treated with strategies out-
lined here. Regarding this manuscript, we will from now on
simply refer to JDM, indicating moderate or severe JDM.
Additionally, the group developed a list of diagnostic tests
that may be useful in patients with JDM. While some of the
tests may be useful for establishing a diagnosis of JDM,
others may be useful to rule out alternative diagnoses or to
assess for potential organ involvement or complications.
Also, myositis-specific antibodies were felt to be an import-
ant aspect of the work-up.
Disease monitoring
It was felt to be important to define a minimum dataset
that should be routinely collected on all patients with at
least moderate JDM (Table 2). The group discussed the
various validated parameters, taking into account the fa-
miliarity of practitioners in Germany with the respective
investigations based on a recently performed online sur-
vey among pediatric rheumatologists and neurologists in
Germany [16, 19, 27–30]. The investigations include
measurements of global, muscular and extramuscular
disease activity, functional impairment, quality of life
and disease damage.
Treatment strategy and treatment targets
The group defined a treat-to-target strategy, which means
treatment to be adjusted according to the achievement of
previously defined targets (Table 3). It was felt that
generally, the initial phase of therapy should be more inten-
sive in order to quickly achieve improvement (“remission
induction”) and avoid undertreatment, with the aim to re-
duce damage, such as contractures, calcinosis and chronic
muscle weakness. The reason for this notion was two-fold:
first, there is a high risk of complications in the acute phase
of the disease, and, second, there is an increased risk for
disease damage with longer duration of active disease [31–
34]. Concerning treatment targets, there was consensus
that at least a moderate improvement should be observed
within 6 weeks after implementing a major change in ther-
apy and at least a major improvement within 12 weeks after
a major change in therapy, with improvement defined ac-
cording to the American College of Rheumatology/Euro-
pean League Against Rheumatism criteria (Table 3) [35].
The consensus on the 12-month goal was to achieve a
glucocorticoid-free treatment regimen. This is similar to
what the CARRA consensus treatment plans state [17].
Specific therapies for juvenile dermatomyositis
Supportive therapies
There was consensus that all patients with JDM should
receive supportive therapy including physical therapy to
prevent contractures, muscle weakness, de-conditioning
and disability. Early return to sports activities is encour-
aged as long as it is safely possible. Effective sun and/or
ultraviolet light protection using avoidance, textile
protection or sunscreen is strongly suggested. Additional
supportive therapies may include hydroxychloroquin
(HCQ), vitamin D or calcium supplementation (Table 4). It
was debated whether HCQ constituted a supportive therapy
or a disease-modifying antirheumatic drug (DMARD) in the
context of JDM, i.e. a medication that may fundamentally
alter the course of disease, in the context of JDM. Eventu-
ally, there was consensus that there is not enough evidence
to consider HCQ a DMARD sensu stricto. Therefore, in
order to avoid the (mis)use of HCQ in case of refractory dis-
ease as a means to intensify therapy, it was opted to define
HCQ as a supportive agent for the purpose of this project.
Glucocorticoid therapies
Different glucocorticoid regimens were preferred by ex-
perts within the panel. Based on the results of a previous
survey [19], 3 glucocorticoid regimens have been listed
which were generally acceptable to the group members
in the treatment of patients with new-onset JDM. The
regimens included an intermittent intravenous methyl-
prednisolone pulse (IVMP) therapy in combination with
either low-to-moderate (prednisone/prednisolone [PDN]
equivalent 0.2–0.5 mg/kg/day) or moderate-to-high-dose
(PDN equivalent 0.5–2 mg/kg max. 60–80 mg/day) gluco-
corticoids, or conventional high-dose oral glucocorticoids
(PDN equivalent 2 mg/kg max. 60–80 mg/day) with or
without a single IVMP pulse (Table 4).
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Tapering of glucocorticoids
No consensus was found concerning a specific tapering
protocol for glucocorticoids. However, the group defined
landmarks for the glucocorticoid taper, i.e. the aim to dis-
continue glucocorticoids after 12 months of therapy, and,
in case of initial high-dose oral glucocorticoid therapy,
PDN doses of 50, 25 and 12.5% 2 months, 4 months and
6 months after initiation of therapy, respectively (Table 4).
Choice of initial disease-modifying antirheumatic drug therapy
There was consensus that all patients with at least moderate
JDM should receive MTX therapy, preferentially subcutane-
ously, or, if there was intolerance to MTX, an alternative
disease-modifying antirheumatic drug (DMARD) therapy,
such as AZA, CSA or MMF. Furthermore, there was con-
sensus that high-dose IVIG may be used in conjunction
with DMARD therapy, especially in case of severe JDM
(Table 4). However, specific regimens of IVIG therapy were
not addressed.
Treatment of refractory disease
The expert group considered refractory disease to be
present if the predefined treatment targets were not
reached. Furthermore, patients with longstanding (i.e.
not new-onset) JDM may be treated according to strat-
egies outlined here. The group considered two options
to be viable under these circumstances: (1) Additional
therapy with another DMARD, specifically, AZA, calcine-
urin inhibitos (CSA or tacrolimus), CYC, IVIG, MMF,
RTX or TNFi, or (2) changing therapy to one of these
medications. However, there was no consensus on which
specific sequence of medications would be preferred. In
order to reflect this uncertainty, the medications or medi-
cation classes are simply listed alphabetically (Table 4).
Developing a treatment strategy
The statements developed are condensed in Fig. 1. Pa-
tients with JDM may enter the treatment strategies out-
lined before either with new-onset disease or with
existing long-standing disease. Patients with new-onset
JDM are treated with one of the glucocorticoid regimens
and a DMARD, preferentially MTX, whereas treatment
Table 1 Diagnosis of juvenile dermatomyositis and case
definitions
Statements Consensus
Diagnosis 100%
For the diagnosis of juvenile dermatomyositis,
the following findings should be present prior
to age 18 years:
• Typical skin finding (heliotrope and/or Gottron-
sign/−papules)
Additional criteria:
• Symmetric proximal muscle weakness and/or
myalgia
• Increased muscle-related enzymes (creatine
kinase, glutamate oxaloacetate transaminase, lactate
dehydrogenase and/or aldolase)
• Typical findings on muscle biopsy
• Typical findings on magnetic resonance imaging
Other possible etiologies should be excluded.
Probable JDM: Skin findings and at least 2 additional criteria
Definite JDM: Skin findings and at least 3 additional criteria
Case definition 92%
The treatment strategies discussed below apply to patients
with active moderately severe or severe juvenile
dermatomyositis.
Patients with severe juvenile dermatomyositis fulfill at least
one of the following characteristics and none of these
characteristics is present in patients with moderate JDM:
• Age < 1 year
• Requirement for intensive care therapy
• Marked disability as measured by being bedridden,
childhood myositis assessment scale (CMAS) < 15 or
manual muscle testing (MMT)8 < 30
• Relevant pulmonary disease
• Myocarditis
• Vasculitis with organ involvement (gastrointestinal
tract, kidney, lungs or central nervous system)
• Aspiration or marked dysphagia
• Severe cutaneous ulceration
• Significant calcinosis
Diagnostic work-up 100%
Obtaining the following parameters may be useful
in case of probable or definite JDM:
• Laboratory tests:
o Enzymes (creatine kinase, glutamate oxaloacetate
transaminase, glutamate pyruvate transaminase,
lactate dehydrogenase, aldolase)
o Complete blood count with differential count
o Routine serum chemistry panel
o Inflammatory markers (C-reactive protein, erythrocyte
sedimentation rate)
o Antinuclear antibody (ANA)
o In case of positive ANA: anti-ds-DNA, anti-PM-Scl, Sm
antibodies, anti-SS-A, anti-SS-B and anti-U1RNP antibodies
o Extended myositis-blot/myositis-specific antibody (incl.
Anti-synthetase, anti-MDA5, anti-Mi-2, anti-NXP-2, anti-SRP,
anti-TIF-1-γ antibodies)
o Immunoglobulin (Ig)G, IgA, IgM
o Complement (CH50)
o Von Willebrand factor-antigen
o Troponin
o TSH
o Immunization status
o Urinalysis
o Stool for occult blood
• Further testing:
o Electrocardiography
o Echocardiography
Table 1 Diagnosis of juvenile dermatomyositis and case
definitions (Continued)
Statements Consensus
o Magnetic resonance imaging (incl. Short tau
inversion recovery or equivalent sequences)
o Chest X-ray
o Abdominal ultrasound
o Muscle ultrasound
o Muscle biopsy
o Bodyplethysmography with
CO-diffusion capacity
o Capillary microscopy
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with existing and active JDM may enter the strategies
later. An essential part of the treatment strategies is the
treat-to-target concept, i.e. the need for frequent moni-
toring of disease activity and adjustment of treatment if
treatment targets are not reached.
Discussion
Based on data on the current clinical practice in Germany
we defined consensus-based statements and strategies
supporting the diagnosis and the management of JDM.
The expert panel consisted both of pediatric neurologist
and rheumatologists with all of them having practical ex-
perience in managing JDM. The group supports the use of
“adapted” Bohan and Peter criteria for the diagnosis of
JDM, including the use of specific MRI findings as a Bohan
and Peter “equivalent” criterion, similar to what others have
proposed in the past [2]. There are a variety of diagnostic
tests that are frequently employed in Germany to assist in
the diagnosis and assessment of patients with JDM, and
therefore are represented here. More recent developments,
such as the discovery of myositis-specific antibodies (MSAs)
that may be rather specific to JDM when compared to adult
DM are also included, and it is felt that these antibodies
may have diagnostic and prognostic value [36–39]. We de-
fined, to our knowledge for the first time, an explicit
treat-to-target strategy for the management of JDM using
the recently developed ACR/EULAR response criteria indi-
cating absent, minimal, moderate or major improvement
for formal assessment of treatment response [35]. Notably,
others have shown that aggressive therapy of JDM using
treatment targets may lead to improved outcome [8]. Simi-
larly, the North American CARRA plans guide treatment
decisions based on whether patients are unchanged, wors-
ening, or experiencing medication side effects or disease
complications [17]. The European SHARE recommenda-
tions focus on whether improvement is present or absent to
guide treatment decisions but does not precisely delineate
time frames for improvement [16]. The treat-to-target con-
cept focusses on strategy rather than on specific treatment
modalities which, for example, has been proven superior to
conventional therapy in rheumatoid arthritis [40]. While
the overall goal of therapy was defined as clinical inactive
disease, we did not define this further during the consensus
conference. However, we think that it would be reasonable
to apply the validated set of criteria by either IMACS or
PRINTO [41, 42].
Since there is a relative lack of data from randomized
controlled clinical trials (RCTs), and since it is unlikely
that large-scale RCTs for JDM will take place, one possible
solution to gather more information on the efficacy or inef-
ficacy of various treatments may be to collect “real life” data
on disease outcome, i.e. to pursue comparative effectiveness
research [43]. An important prerequisite for comparative
effectiveness research is the application of uniform and
harmonized treatments. Therefore, the harmonization
of existing clinical practice has been an important goal
for this project. Furthermore, the regular collection of a
dataset in patients with JDM is of utmost importance
to allow comparison of clinical outcomes, not only
nationally but also internationally. Consequently, our
statements include the minimal dataset agreed upon by
international experts [29].
These harmonized consensus strategies overall fit ra-
ther well into the above-mentioned framework set up by
the CARRA consensus treatment plans and the SHARE
Table 2 Monitoring parameters for patients with juvenile
dermatomyositis
Statement Consensus
Disease monitoring tools 100%
In order to monitor disease activity and disease damage
over time, the regular measurement of the following
parameters may be useful (initially every 6 weeks, later
every 3 months):
• Length, weight, blood pressure
• Physician global assessment of disease activity (visual
analog scale 0–10)
• Parent/Patient global assessment of disease activity
(visual analog 0–10)
• Manual muscle testing (MMT)8 and/or Childhood
Myositis Assessment Scale (CMAS)
• Childhood Health Assessment Questionnaire (CHAQ)
• A validated Quality of life instrument
• Muscle enzymes
• Extramuscular disease activity, e.g. via Disease Activity
Score, Myositis Disease Activity Assessment Tool or Visual
Analog Scale
• Myositis damage index (annually)
Table 3 Treatment targets and treatment strategy
Statements Consensus
Treatment targets 100%
The overall goal is clinical inactive disease
within 1 year after initiation of therapy, ideally
under a glucocorticoid-free treatment regimen.
Under some circumstances,
low-dose glucocorticoids or intermittent intravenous
methylprednisolone pulse therapy may be acceptable.
The following interim improvementa is targeted:
• At least a moderate improvement within 6 weeks after
initiation or substantial change in therapy.
• At least a major improvement within 3 months after
initiation or substantial change in therapy.
General treatment strategy 92%
The consensus treatment strategies for JDM serve to
harmonize existing therapies in clinical practice.
The treatment strategy generally consists of a treat-to-target
strategy, i.e. therapies are modified according to reaching
or failing previously established targets. In addition, there
is a more intensive first (induction) treatment phase
(6–8 weeks) and a less intensive subsequent (maintenance)
phase.
Components of the initial therapy include glucocorticoids
and glucocorticoid-sparing DMARDs.
a American College of Rheumatology/European League Against Rheumatism
criteria (categories: no, minimal, moderate, major improvement) [34]
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recommendations which had been developed previously
or simultaneously, respectively. However, there are im-
portant differences in clinical practice in Germany when
compared to this framework. For example, practitioners in
Germany have a strong preference to choose a gluco-
corticoid regimen consisting of ongoing intermittent
IVMP therapy in combination with low-to-moderate dose
glucocorticoids instead of conventional daily high-dose
glucocorticoid regimens [19]. There is surprisingly little
data available on this important question. Proponents of
intermittent IVMP pulse therapy suspect similar efficacy
to high-dose daily glucocorticoids but less adverse effects,
whereas other data suggest it may be less efficacious
[7, 44, 45]. However, there are no definitive data that
demonstrate superiority of one glucocorticoid regimen
over another. Regarding treatment choices in case of
severe or refractory JDM, there is a strong preference
for IVIG, similar what is outlined in the CARRA treat-
ment plans. Finally, the group agrees that patients with
JDM should be managed in centers with an expertise in
JDM. Furthermore, it is of course assumed that treatment
decisions should always be shared between patients, fam-
ilies and providers. Since centers participating in the final
consensus meeting manage more than half of all regis-
tered patients with JDM in Germany, it can be assumed
that the consensus reached here is broadly generalizable
in Germany. We have carefully worded the statements so
that they are not confused with treatment guidelines or
strict treatment recommendations.
There are several limitations to the PRO-KIND con-
sensus strategies for JDM. First, the concepts outlined
here may not represent the optimal way to manage JDM
but rather represent current clinical practice among
JDM experts in Germany and are based on a low level of
evidence. Second, the statements and resulting strategies
do not represent treatment protocols or “To Do”-lists.
Management of patients with JDM will remain highly vari-
able. Third, the field is constantly evolving: Some MSAs
that were only recently reported in children, for example,
anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR) antibodies, are not included in our list but may
be useful to determine in some patients, especially in case
of refractory myositis [37, 46–48]. Fourth, some of the
statements are rather vague, for example tapering of
Table 4 Therapies used in juvenile dermatomyositis
Statements Consensus
Supportive therapy 100%
Early and intensive physical therapy is essential
in order to avoid contractures and improve/maintain
muscle strength, even during active myositis.
Participation in sports is desirable after individual
counseling. Effective sun protection is essential, incl.
textile protection and sunscreen.
The following treatments may be considered
individually:
• Supplementation of vitamin D, e.g. depending
on 25-OH
vitamin D level, glucocorticoid treatment and/or
bone mineral density
• Supplementation of calcium, e.g. in case of insufficient
intake
• Hydroxychloroquin
Initial glucocorticoid therapy 92%
The principal glucocorticoid strategy options include
• Intermittent intravenous methylprednisolone pulse
(IVMP) therapy + moderate-to-high-dose daily
glucocorticoids (prednisone equivalent 0.5–2 mg/kg
[max. 80 mg] daily)
• Intermittent IVMP therapy + lower-to-moderate
dose daily glucocorticoids (prednisone equivalent
0.2–0.5 mg/kg daily)
• High-dose daily glucocorticoid therapy (2 mg/kg
[max. 60–80 mg] daily) +/− initial single IVMP pulse
Glucocorticoid tapering 92%
The following landmarks may be applied when
tapering glucocorticoids, assuming an adequate
treatment response (i.e. treatment targets are reached):
• IVMP
o 20–30 mg/kg (max. 1000 mg) daily × 3 days
o At 2 and 4 weeks, subsequently every 4–6
weeks × 6–12 months
• High-dose daily glucocorticoids (prednisone or
prednisolone)
o 2 mg/kg (max. 60–80 mg) × 1 month, then start
taper
o 50% of initial dose at 2 months, 25% at 4 months,
12.5% at 6 months, discontinue at 12 months
• Moderate-dose daily glucocorticoids (0.5–2 mg/kg
daily, < 60 mg daily)
o Stop within 12 months
• Lower-dose daily glucocorticoids (< 0.5 mg/kg daily)
o Stop within 12 months
Glucocorticoid-sparing therapies 100%
The following glucocorticoid-sparing therapies are
used in the initial treatment:
• Methotrexate (MTX) 15–20 mg/m2 (max. 30 mg)
once weekly (s.c. preferred)
• MTX 15–20 mg/m2 (max. 30 mg) once weekly (s.c.
preferred) + intravenous immune globulins (IVIG)
(especially in case of severe juvenile dermatomyositis)
In case of MTX intolerance, MTX can be replaced by
azathioprin (AZA), cyclosporin A (CSA) or mycophenolate
mofetil (MMF).
Refractory disease 92%
In case of not reaching predefined targets (Table 3)
or disease flare, a change in therapy is required. In this
situation, current therapies should be intensified,
exchanged and/or another therapy added.
Table 4 Therapies used in juvenile dermatomyositis (Continued)
Statements Consensus
Further treatment should be discussed individually
with experts. The following agents are generally used:
AZA, calcineurin inhibitors, cyclophosphamide,
IVIG, MMFmycophenolate mofetil, rituximab, tumor
necrosis factor inhibitors
Abbreviations: AZA azathioprin, CSA cyclosporin A, IVIG intravenous immune
globulins, IVMP intravenous methylprednisolone pulse, JDM juvenile
dermatomyositis, MTX methotrexate, MMF mycophenolate mofetil,
s.c. subcutaneously
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glucocorticoids, the choice of DMARD therapy beyond
MTX, DMARD dosing regimens and the definitions of
clinical inactive disease or disease flare. This is in part due
to the difficulties achieving consensus on more precise
statements which, in turn, results from the lack of convin-
cing evidence for the preference of one option over an-
other. We attempt to circumnavigate these issues by the
implementation of a stringent treat-to-target strategy as
outlined above. Fifth, many of the treatment options out-
lined in our strategies are not legally approved for the
treatment of JDM, including the standard treatment with
MTX. Therefore, treatment choices for individual patients
may need to be adjusted based on local regulations for the
off-label use of certain drugs. Sixth, some of the treatment
options may not be widely available, again either due to
regulation or due to cost.
Conclusions
In summary, we have developed consensus-based strat-
egies for the diagnosis, monitoring and treatment of JDM
by the harmonization of current clinical practice with the
overarching goal is to improve the outcome of patients
with JDM. Concerning therapy, we are placing an em-
phasis on a treat-to-target strategy using internationally
accepted improvement criteria rather than on individual
medications, fitting well into existing frameworks. As
Fig. 1 Treatment strategies in juvenile dermatomyositis (JDM). Patients with new-onset active JDM are treated with 1 of 3 glucocorticoid
regimens and always receive an additional disease-modifying antirheumatic drug, preferably methotrexate with or without intravenous immune
globulins. If the predefined treatment targets are achieved, glucocorticoids are tapered according to a scheduled outlined in Table 3. If treatment
targets are not reached, a modification in therapy is needed, i.e. either addition of a new therapy or switching therapy. There was no consensus
as to a specific sequence of changes in therapy. Patients may also be treated according to these strategies if they have pre-existing, active JDM
(see right side of this figure). *Repeated cycles of intravenous methylprednisolone 20–30 mg/kg (max. 1000 mg) daily for 3–5 days in a row.
**Prednisone equivalent 0.5–2 mg/kg (max. 80 mg) daily. †Prednisone equivalent 0.2–0.5 mg/kg daily. ‡Prednisone equivalent 2 mg/kg (max.
80 mg) daily. ¶Single cycle of intravenous methylprednisolone 20–30 mg/kg (max. 1000 mg) daily for 3–5 days. Abbreviations: AZA, azathioprin;
CSA, cyclosporin A; CYC, cyclophosphamide; DMARD, disease-modifying antirheumatic drug; GC, glucocorticoids; IVIG, intravenous immune
globulins; IVMP, intravenous methylprednisolone pulse; JDM, juvenile dermatomyositis; MTX, methotrexate; MMF, mycophenolate mofetil; RTX,
rituximab; s.c., subcutaneously; TNFi, tumor necrosis factor inhibitor
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others have done previously, we define a minimal dataset
to regularly collect in patients with JDM in order to allow
comparative effectiveness research. We conclude that, due
to the rarity of the condition, international collaboration
will be critical in order to improve the outcome of patients
with JDM. We believe that this work will add to the arma-
mentarium of providers managing patients with JDM
worldwide.
Acknowledgements
The authors thank Dipl.-Psych. Dr. Lea Höfel for her valuable support as a
moderator at the consensus meeting. We are also grateful for the help of
Jana Hörstermann with surveys and Nils Geisemeyer with data analyses; both
are from the German Rheumatism Research Centre Berlin (DRFZ). The
authors thank member of the GKJR and the GNP for their participation in the
survey that assessed the current clinical practice in Germany.
Funding
The national pediatric rheumatology database is funded by the German
Children’s Arthritis Foundation (Deutsche Kinderrheumastiftung). The
publication fees were supported by the Initiative für das rheumakranke Kind
(www.irkk.de), a non-profit organization advocating for improved well-being
of children with rheumatic diseases and their families, and a directed donation
by the U can ride for arthritis (http://www.ucanr4a.eu/en/bicycle/) initiative.
Availability of data and materials
All data generated or analyzed during this study are included in this article.
Authors’ contributions
CH participated in online surveys, the consensus meeting, analyzed data
from the registries and survey and drafted the manuscript. FD, HF, JPH, AU
and FWH developed the revised diagnostic criteria, participated in online
surveys and the consensus meeting, and revised the manuscript critically. JB,
FD, HF, DF, WMF, UN, CR and TS participated in the final consensus
conference and revised the manuscript critically. EL and FS were members of
the expert panel, participated in online surveys and revised the manuscript
critically. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The national pediatric rheumatology database was approved by the ethics
committee of the Charité in Berlin.
Consent for publication
Not applicable.
Competing interests
Dr. Hinze has received consulting fees, speaking fees, and/or honoraria from
Novartis (less than $10,000 each). Dr. Oommen reports no potential
competing interests. Dr. Dressler has received consulting fees, speaking fees,
and/or honoraria from Novartis and Pfizer (less than $10,000 each). Dr.
Weller-Heinemann has received honoraria from Abbvie, Novartis and Pfizer
(less than $10,000 each). Dr. Lainka has received consulting fees, speaking
fees, and/or honoraria from Novartis (less than $10,000 each) and research
support from Sobi. Dr. Brunner has received consulting fees, speaking fees,
and/or honoraria from Abbvie, MSD, Novartis, Pfizer and Roche (less than
$10,000 each). Dr. Föll is a board member of the Society for Pediatric Rheumatoloy
and has received honoraria from Novartis, Pfizer, Roche-Chugai and Sobi (less than
$10,000 each) and research support from Novartis and Pfizer. Dr. Neudorf has
received consulting fees, speaking fees, and/or honoraria from Chugai and Philips
(less than $10,000 each), and research support from Novartis. Dr. Schwarz reports
no potential competing interests. Dr. Schara is president of the Gesellschaft für
Neuropädiatrie (GNP; Society for Pediatric Neurology in Germany) and has
received consulting fees, speaking fees, and/or honoraria from PTC Therapeutics,
Deutsche Myasthenie Gesellschaft (German Myasthenia Society) and benni &co (a
non-profit organization benifitting patients with muscular dystrophy). Dr. Haas is
the president of the Society for Pediatric Rheumatology has received research
support from Novartis and Pfizer.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Pediatric Rheumatology and Immunology, University
Hospital Münster, Albert-Schweitzer-Campus 1, Building D3, 48149 Münster,
Germany. 2Department of Pediatric Oncology, Hematology and Clinical
Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.
3Department of Pediatric Pulmonology, Allergy and Neonatology, Hanover
Medical School, Hanover, Germany. 4Department of Pediatrics, St. Mary’s
Hospital, Amberg, Germany. 5Division of Pediatric Rheumatology, Prof. Hess
Children’s Hospital, Bremen, Germany. 6Division of Pediatric Rheumatology,
University Medicine, Rostock, Germany. 7Division of Immunology, Bone
Marrow Transplantation and Rheumatology, University Hospital Ulm, Ulm,
Germany. 8Department of Pediatrics, University Hospital Essen, Essen,
Germany. 9Department of Pediatrics, Medical University Innsbruck, Innsbruck,
Austria. 10German Center for Pediatric and Adolescent Rheumatology,
Garmisch-Partenkirchen Department of Dermatology, Oberammergau Center
for Rheumatic Diseases, Oberammergau, Germany. 11Department of Pediatric
Neurology, University Hospital Munich, Munich, Germany. 12Department of
Pediatrics, Clementine Children’s Hospital, Frankfurt, Germany. 13Department
of Pediatric Rheumatology, St. Josef Hospital, Sendenhorst, Germany.
14Department of Pediatric Neurology, University Hospital Essen, Essen,
Germany.
Received: 1 March 2018 Accepted: 13 June 2018
References
1. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis
and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;
371(9631):2201–12.
2. Brown VE, Pilkington CA, Feldman BM, Davidson JE, Network for Juvenile
Dermatomyositis PRES. An international consensus survey of the diagnostic
criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;
45(8):990–3.
3. Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, Lindsley CB,
Ota S, Pilkington C, Reed AM, et al. Treatment approaches to juvenile
dermatomyositis (JDM) across North America: the childhood arthritis and
rheumatology research alliance (CARRA) JDM treatment survey. J
Rheumatol. 2010;37(9):1953–61.
4. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn
RJ, Feldman BM, Harris-Love MO, Koontz DC, et al. Rituximab in the treatment of
refractory adult and juvenile dermatomyositis and adult polymyositis: a
randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.
5. Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M,
Magnusson B, Sterba G, Avcin T, et al. Prednisone versus prednisone plus
ciclosporin versus prednisone plus methotrexate in new-onset juvenile
dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.
6. Dressler F, Huppertz HI. Juvenile dermatomyositis. Z Rheumatol. 2006;65(7):
587–90. 592-584
7. Huppertz HI, Frosch M, Kuhn C, Christen HJ. Treatment of juvenile
dermatomyositis (JDM) with highdose oral steroids or with steroid pulse
therapy. Arthritis Rheum. 1998;41(9 Suppl):S264.
8. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP.
Complete and sustained remission of juvenile dermatomyositis resulting
from aggressive treatment. Arthritis Rheum. 2009;60(6):1825–30.
9. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig
therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089–94.
10. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM.
Pharmacokinetic study of oral prednisolone compared with intravenous
methylprednisolone in patients with juvenile dermatomyositis. Arthritis
Rheum. 2008;59(2):222–6.
11. Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot
study of etanercept in patients with refractory juvenile dermatomyositis.
Arthritis Care Res (Hoboken). 2014;66(5):783–7.
12. Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate
mofetil: a possible therapeutic agent for children with juvenile
dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–51.
Hinze et al. Pediatric Rheumatology  (2018) 16:40 Page 8 of 9
13. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA.
Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A
review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6.
14. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of
juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664–75.
15. Bundesausschuss G. Arzneimittel-Richtlinie/ Anlage VI: Off-Label-Use
Intravenöse Immunglobuline (IVIG) bei Polymyositis und bei
Dermatomyositis. Bundesanzeiger. 2013. https://www.g-ba.de/
informationen/beschluesse/1701/.
16. Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman
BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, et al. Consensus-based
recommendations for the management of juvenile dermatomyositis. Ann
Rheum Dis. 2017;76(2):329–40.
17. Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S,
Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, et al.
Consensus treatments for moderate juvenile dermatomyositis: beyond
the first two months. Results of the second childhood arthritis and
rheumatology research alliance consensus conference. Arthritis Care Res
(Hoboken). 2012;64(4):546–53.
18. Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K,
Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S,
Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML,
Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H,
Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM,
Patwardhan A. Biologic therapies for refractory juvenile dermatomyositis: five
years of experience of the Childhood Arthritis and Rheumatology Research
Alliance in North America. Pediatr Rheumatol. 2017;15(1).
19. Hinze CH, Speth F, Oommen PT, Haas J-P: Current management of juvenile
dermatomyositis in Germany: an online survey of pediatric rheumatologists
and pediatric neurologists in Germany. 2018.
20. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K,
Aringer M, Bootsma H, Boumpas D, Bruce IN, et al. Treat-to-target in
systemic lupus erythematosus: recommendations from an international task
force. Ann Rheum Dis. 2014;73(6):958–67.
21. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B,
Flader C, Kay J, Matsuoka M, et al. Treat-to-target (T2T) recommendations
for gout. Ann Rheum Dis. 2017;76(4):632–8.
22. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G,
Combe B, Cutolo M, de Wit M, Dougados M, et al. Treating rheumatoid
arthritis to target: recommendations of an international task force. Ann
Rheum Dis. 2010;69(4):631–7.
23. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-
to-target approach in the management of juvenile idiopathic arthritis. Clin
Exp Rheumatol. 2012;30(4 Suppl 73):S157–62.
24. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis:
hitting the target. Nat Rev Rheumatol. 2015;11(5):290–300.
25. Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N,
Hufnagel M, Jansson AF, Hedrich C, et al. Practice and consensus-based
strategies in diagnosing and managing systemic juvenile idiopathic arthritis
in Germany. Pediatr Rheumatol Online J. 2018;16(1):7.
26. Horneff G, Klein A, Ganser G, Sailer-Hock M, Gunther A, Foeldvari I, Weller-
Heinemann F. Protocols on classification, monitoring and therapy in children's
rheumatology (PRO-KIND): results of the working group Polyarticular juvenile
idiopathic arthritis. Pediatr Rheumatol Online J. 2017;15(1):78.
27. Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt
J, Oakley P, Benveniste O, Danieli MG, Danko K, et al. The EuroMyositis
registry: an international collaborative tool to facilitate myositis research.
Ann Rheum Dis. 2018;77(1):30–9.
28. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray
KJ, Pilkington CA, Juvenile Dermatomyositis Research G. The juvenile
dermatomyositis National Registry and repository (UK and Ireland)–clinical
characteristics of children recruited within the first 5 yr. Rheumatology
(Oxford). 2006;45(10):1255–60.
29. McCann LJ, Kirkham JJ, Wedderburn LR, Pilkington C, Huber AM, Ravelli A,
Appelbe D, Williamson PR, Beresford MW. Development of an
internationally agreed minimal dataset for juvenile dermatomyositis (JDM)
for clinical and research use. Trials. 2015;16:268.
30. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM,
Garay S, Kuis W, Machado C, Pachman L, et al. Preliminary core sets of
measures for disease activity and damage assessment in juvenile systemic
lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford).
2003;42(12):1452–9.
31. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S,
Oliveira SK, Sztajnbok F, Cuttica R, et al. Long-term outcome and prognostic
factors of juvenile dermatomyositis: a multinational, multicenter study of
490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.
32. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC.
Dermatomyositis. J Pediatr. 1964;64:101–31.
33. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis:
factors predicting functional outcome and development of dystrophic
calcification. J Pediatr. 1983;103(6):882–8.
34. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic
implications of histopathology in childhood polydermatomyositis. Arthritis
Rheum. 1982;25(2):126–39.
35. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM,
Cimaz R, Cuttica RJ, de Oliveira SK, et al. 2016 American College of
Rheumatology/European league against rheumatism criteria for minimal,
moderate, and major clinical response in juvenile dermatomyositis: an
international myositis assessment and clinical studies group/Paediatric
rheumatology international trials organisation collaborative initiative.
Arthritis Rheumatol. 2017;69(5):911–23.
36. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy
H, Davidson JE, Cooper RG, McHugh NJ. Clinical associations of
autoantibodies to a p155/140 kDa doublet protein in juvenile
dermatomyositis. Rheumatology (Oxford). 2008;47(3):324–8.
37. Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham
B, Weiss PF, Horkayne-Szakaly I, Targoff IN, et al. Association of Anti-3-
Hydroxy-3-Methylglutaryl-coenzyme a reductase autoantibodies with
DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care
Res (Hoboken). 2017;69(7):1088–94.
38. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies:
pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern
Med. 2016;280(1):24–38.
39. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW,
Childhood Myositis Heterogeneity Collaborative Study G. The myositis
autoantibody phenotypes of the juvenile idiopathic inflammatory
myopathies. Medicine (Baltimore). 2013;92(4):223–43.
40. Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G,
Bykerk V, Dougados M, Emery P, Haraoui B, et al. Evidence for treating
rheumatoid arthritis to target: results of a systematic literature search
update. Ann Rheum Dis. 2016;75(1):16–22.
41. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C,
Wulffraat NM, Malattia C, Garay SM, Hofer M, et al. The PRINTO criteria for
clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;
72(5):686–93.
42. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman
BM, Giannini EH, Miller FW, International Myositis A, et al. International
consensus guidelines for trials of therapies in the idiopathic inflammatory
myopathies. Arthritis Rheum. 2005;52(9):2607–15.
43. DeWitt EM, Brunner HI. The landscape of comparative effectiveness research
in rheumatology. Nat Rev Rheumatol. 2014;10(1):57–62.
44. Lang B, Dooley J. Failure of pulse intravenous methylprednisolone
treatment in juvenile dermatomyositis. J Pediatr. 1996;128(3):429–32.
45. Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone
treatment of juvenile dermatomyositis. Arthritis Rheum. 1987;30(3):328–34.
46. Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M,
Warrier K, Wedderburn LR, McHugh NJ, Juvenile Dermatomyositis Research
G. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory
myopathies identify a rare but clinically important subset of patients. J
Rheumatol. 2017;44(4):488–92.
47. Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks
CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL. More severe disease
and slower recovery in younger patients with anti-3-hydroxy-3-
methylglutaryl-coenzyme a reductase-associated autoimmune myopathy.
Rheumatology (Oxford). 2017;56(5):787–94.
48. Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ,
Endo Y, Komaki H, Fujii T, et al. Pediatric necrotizing myopathy associated
with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
Rheumatology (Oxford). 2017;56(2):287–93.
Hinze et al. Pediatric Rheumatology  (2018) 16:40 Page 9 of 9
